A Methodological Review on the Pharmacokinetic/Pharmacodynamic Integration of Antibacterial Drugs

被引:1
|
作者
Wang, Hongjuan [1 ]
Zhang, Longfei [1 ,2 ,3 ]
Hu, Jianhe [1 ,2 ]
机构
[1] Henan Inst Sci & Technol, Coll Anim Sci & Vet Med, Xinxiang 153003, Henan, Peoples R China
[2] Henan Inst Sci & Technol, Postdoctoral Res Base, Xinxiang 453003, Henan, Peoples R China
[3] Henan Agr Univ, Postdoctoral Res Stn, Zhengzhou 450046, Henan, Peoples R China
关键词
Antibacterial drugs; PK; PD integration model; Multi-drug resistance; Dosage regimen optimization; In vivo PK; PD model; PHARMACODYNAMIC MODELS; PHARMACOKINETICS; SERUM; DANOFLOXACIN; BREAKPOINTS;
D O I
10.9775/kvfd.2021.26849
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Inappropriate application of antimicrobial agents can result in resistance by bacteria to drugs and changes in bacterial ecology. In particular, the emergence of multi-drug resistant bacteria seriously affects the antibacterial efficacy of drugs, which threatens the health and lives of humans and animals. Pharmacokinetic/Pharmacodynamic (PK/PD) models can be used to analyze the relationship between PK and PD data and the antibacterial effect. PK/PD models provide valuable guidance for optimization of dosage regimens, development of new drugs, setting of susceptibility breakpoints, and analyses of resistant mutants. The main models of PK/PD integration are in vitro PK/PD, ex vivo PK/PD, and in vivo PK/PD. Each of these models has its own advantages and disadvantages. Hence, knowing how to choose the appropriate PK/PD model has a huge influence on obtaining accurate PK/PD data. In this review, we describe the commonly used PK/PD methods. In this way, we provide a reference for optimizing drug regimens and preventing and controlling drug-resistant bacterial infections.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 50 条
  • [21] Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
    Dostalek, Miroslav
    Akhlaghi, Fatemeh
    Puzanovova, Martina
    CLINICAL PHARMACOKINETICS, 2012, 51 (08) : 481 - 499
  • [22] TREATMENT OF DEPRESSION WITH TRICYCLIC DRUGS - PHARMACOKINETIC AND PHARMACODYNAMIC ASPECTS
    ASBERG, M
    PHARMAKOPSYCHIATRIE NEURO-PSYCHOPHARMAKOLOGIE, 1976, 9 (01): : 18 - 26
  • [23] Integration and modelling of pharmacokinetic and pharmacodynamic data for marbofloxacin in calves
    Potter, T.
    Illambas, J.
    Rycroft, A.
    Lees, P.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 : 142 - 143
  • [24] Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
    Miroslav Dostalek
    Fatemeh Akhlaghi
    Martina Puzanovova
    Clinical Pharmacokinetics, 2012, 51 (8) : 481 - 499
  • [25] Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
    Romano Danesi
    Stefano Fogli
    Alessandra Gennari
    Pierfranco Conte
    Mario Del Tacca
    Clinical Pharmacokinetics, 2002, 41 : 431 - 444
  • [26] PHARMACODYNAMIC AND PHARMACOKINETIC MEASUREMENTS IN CARDIOVASCULAR-RENAL DRUGS
    HAYES, AH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1974, 16 (01) : 201 - 211
  • [27] Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs
    Danesi, R
    Fogli, S
    Gennari, A
    Conte, P
    Del Tacca, M
    CLINICAL PHARMACOKINETICS, 2002, 41 (06) : 431 - 444
  • [28] Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus
    Bialer, Meir
    EPILEPSIA, 2009, 50 : 44 - 48
  • [29] Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs
    Anderson, Gail D.
    THERAPEUTIC DRUG MONITORING, 2008, 30 (02) : 173 - 180
  • [30] Pharmacodynamic and pharmacokinetic aspects of opiate drugs and opioid peptides
    Burks, T
    DRUG ABUSE IN THE DECADE OF THE BRAIN, 1997, : 63 - 69